Cargando…

Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer

PURPOSE: Local treatment has become a treatment option for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Subgroup analyses based on a history of cerebrovascular disease (CVD) were performed to evaluate the impact thereof on overall survival (OS) after local treatment. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Jin, Yu, Young Dong, Park, Dong Soo, Rha, Koon Ho, Hong, Sung Joon, Cho, Kang Su, Chung, Byung Ha, Koo, Kyo Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881707/ https://www.ncbi.nlm.nih.gov/pubmed/31769243 http://dx.doi.org/10.3349/ymj.2019.60.12.1129

Ejemplares similares

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
por: Hah, Yoon Soo, et al.
Publicado: (2019)

Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy
por: Kim, Do Kyung, et al.
Publicado: (2018)

Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring
por: Lee, Dong Hoon, et al.
Publicado: (2014)

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Analgesic Opioid Dose Is an Important Indicator of Postoperative Ileus Following Radical Cystectomy with Ileal Conduit: Experience in the Robotic Surgery Era
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence
por: Kim, Dae Keun, et al.
Publicado: (2016)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Laparoendoscopic Management of Midureteral Strictures
por: Komninos, Christos, et al.
Publicado: (2014)

The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population
por: Park, Jee Soo, et al.
Publicado: (2019)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?
por: Park, Jee Soo, et al.
Publicado: (2019)

Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients
por: Shiota, Masaki, et al.
Publicado: (2021)

Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer
por: Lee, Seung Hwan, et al.
Publicado: (2015)

Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry
por: Lee, Kwang Suk, et al.
Publicado: (2018)

Pathological Characteristics of Prostate Cancer in Men Aged < 50 Years Treated with Radical Prostatectomy: a Multi-Centre Study in Korea
por: Chung, Mun Su, et al.
Publicado: (2019)

Can microfocal prostate cancer be regarded as low-risk prostate cancer?
por: Lee, Seung Hwan, et al.
Publicado: (2013)

Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience
por: Guin, Sunny, et al.
Publicado: (2022)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
por: Oh, Kyung Tak, et al.
Publicado: (2020)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Role of the elastography strain ratio using transrectal ultrasonography in the diagnosis of prostate cancer and clinically significant prostate cancer
por: Yoo, Jeong Woo, et al.
Publicado: (2022)

Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Extended lymph node dissection in robot-assisted radical prostatectomy: lymph node yield and distribution of metastases
por: Kim, Kwang Hyun, et al.
Publicado: (2014)

Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry
por: Hah, Yoon Soo, et al.
Publicado: (2018)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer
por: Kim, Dong Gyun, et al.
Publicado: (2022)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Clinical Experiences of Incidental Prostate Cancer after Transurethral Resection of Prostate (TURP) According to Initial Treatment: A Study of a Korean High Volume Center
por: Lee, Dong Hoon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0dk0gj0b3k54tvo4btbfri1vgu